Regulatory milestones

Amarin Corp. plc (NASDAQ:AMRN) fell $0.54 (25%) to $1.64 last week after disclosing that FDA said it no longer considers a change in serum triglyceride levels sufficient to "establish the effectiveness" of a compound for reducing cardiovascular risk in patients with triglyceride levels less than 500 mg/dL.